New schemes

Helicobacter pylori, nucleic acid detection

Labquality is announcing a new EQA scheme for nucleic acid detection of Helicobacter pylori. The scheme will be suitable for different methods.

The registration for this pilot study is closed.

Maternal Serum Screening

Labquality is announcing a new EQA scheme for Maternal serum screening suitable for first and/or second-trimester screenings including analytes AFP, b-hCG, Inhibin A, PAPP-A, total hCG and unconjugated Estriol.

The registration for this pilot study is closed.

Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection

Labquality is announcing a new EQA scheme for Mycoplasma genitalium, drug resistance multiplex, nucleic acid detection. The scheme is suitable for nucleic acid assays detecting Mycoplasma genitalium and mutations
in the 23S rRNA gene that are associated with resistance to azithromycin (macrolide antibiotic).

The registration for this pilot study is closed.

Pipette control

Labquality is announcing a new EQA scheme for controlling and monitoring single-channel piston pipettes used in clinical laboratories. This EQA scheme offers the possibility for clinical laboratories to perform intermediate performance checks between pipette calibration intervals including interlaboratory comparison and individual performance assessment against a reference measurement value.

The registration for this pilot study is closed.

Salivary Cortisol

Labquality is announcing a new EQA scheme for Salivary Cortisol. The scheme is suitable for different assays measuring salivary cortisol in clinical samples. The registration for this pilot study is closed. 

Chemokine CXCL13

Labquality is announcing a new EQA scheme for Chemokine CXCL13, a biomarker for neuroborreliosis. Pilot round includes two samples that should be analysed as regular patient samples. The registration for this pilot study is closed.

Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis

Labquality is announcing a new EQA scheme for Interferon Gamma Release Assay (IGRA) for Mycobacterium tuberculosis. The scheme is suitable for different ELISA assays measuring the cell-mediated response to specific tuberculosis antigens in whole blood. The sample sets are sold out and we can only accept registrations for a waiting list. The registration for this pilot study is closed. 

Faecal Elastase

Labquality is announcing a new EQA scheme for faecal elastase. In the pilot study, two lyophilized faecal samples of different elastase concentration will be included. The registration for this pilot study is closed. 

Fungal infections, nucleic acid detection

Labquality is announcing a new EQA scheme for direct nucleic acid detection of fungal infections. The scheme samples may contain yeasts, moulds and dermatophytes and it will be suitable for different nucleic acid test panels. The registration for this pilot study is closed. 

Mycobacterium tuberculosis, rifampicin and isoniazid, nucleic acid detection

Labquality is announcing a new EQA scheme for nucleic acid detection of Mycobacterium tuberculosis including samples containing rifampicin and isoniazid resistance. The scheme is suitable for nucleic acid test panels and scoring is based on qualitative interpretation. The registration for this pilot study is closed. 

Adrenocorticothropic hormone ACTH and Cortisol

Labquality is announcing a new pilot study for two hormones ACTH and cortisol. The registration for this pilot study is closed. 

HSV1&2 / VZV / T. pallidum, nucleic acid detection

Labquality is announcing a new pilot study for nucleic acid detection of four pathogens included in a four-plex sample. The included pathogens are HSV1&2, VZV and Treponema pallidum. The registration for this pilot study is closed. 

EQA for next-generation sequencing methods

We are developing external quality assessments for NGS methods in microbiology. If you are interested, please contact us!